PRECISION BIOSCIENCES INC
For the period ended Jun 30, 2024. Filed Aug 1, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 1, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
On May 8, 2024, we issued 25,000 shares of our common stock in a non-brokered private placement (the “Private Placement”) to certain members of our management (the “Investors”) at an offering price of $12.00 per share, resulting in approximately $300,000 in aggregate gross proceeds. The Private Placement closed on May 8, 2024. We intend to use the net proceeds of the Private Placement to fund ongoing research and development initiatives.
The Investors in the Private Placement included (1) Michael Amoroso, President and Chief Executive Officer of the Company and a member of the Company’s board of directors, (2) Alex Kelly, Chief Financial Officer of the Company, (3) Dario Scimeca, General Counsel of the Company, and (4) Jeff Smith, Chief Research Officer of the Company.
The offer and sale of the shares of our common stock in the Private Placement were not registered under the Securities Act of 1933, as amended, in reliance upon the exemption from registration provided by Section 4(a)(2) thereunder as a transaction by an issuer not involving any public offering.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.